 SAN DIEGO, July 1, 2021 PRNewswire -- Kintara Therapeutics, Inc. Nasdaq: KTRA Kintara or the Company, a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, today announced topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083 being conducted at the MD Anderson Cancer Center MD Anderson in Houston, Texas. The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase MGMT gene. 